uniQure N.V.

QURE

Held by 4 specialist biotech funds

High Convergence

Share on X

Fund Holdings

4 fund convergence

Avoro Capital Advisors RTW Investments OrbiMed Advisors

Position Trend

Feb 13, 2026

$11.9M

1 fund

Feb 17, 2026

$106.5M

2 funds

Mar 16, 2026

$147.2M

1 fund

+1134% total institutional value over 3 quarters

Catalysts

No catalysts tracked.

Position Details

Avoro Capital AdvisorsNEWMar 16, 2026

Shares: 6,150,000Value: $147.2M

# Signal Note: Avoro Capital Initiates $147M Position in uniQure Avoro's entry into QURE suggests confidence in the company's gene therapy pipeline, likely driven by upcoming catalysts around eteplirsen (Exondys 51) lifecycle management or clinical readouts in its proprietary programs (AMT-130 for Huntington's disease in Phase 2b). The timing of this significant position size—representing ~6% of shares outstanding—indicates the firm may be positioning ahead of near-term binary events or undervalued IP assets given gene therapy sector volatility.

RTW InvestmentsNEW

More QURE Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

ARGX4 funds CELC4 funds APLS3 funds RNA3 funds IRON3 funds AXSM3 funds PTCT3 funds UTHR

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# Signal Note: RTW Investments Initiates $88.8M Position in uniQure RTW's substantial entry into QURE signals conviction in the company's gene therapy pipeline, likely driven by near-term catalysts in its lead programs: eteplirsen for Duchenne muscular dystrophy (commercial stage) and AMT-161 for hemophilia B (Phase 2b expected data 2024-2025). The $88.8M stake represents meaningful capital deployment by a data-focused fund, suggesting positive risk-reward on clinical/commercial inflection points ahead.